|
Medicines Authority Circular No P08/2008 Re: Use
of Angiotensin II Receptor Inhibitors during Pregnancy
- 02.05.2008
Medicines Authority Circular No P07/2008 Re: Further
data needed to determine risk of heart attack with abacavir
- 09.04.2008
Medicines
Authority Circular No P06/2008 Re: EMEA
concludes new advice to doctors and patients for Tysabri (natalizumab)
needed - 09.04.2008
Medicines Authority Circular No P05/2008 Re: EMEA
recommendation of a new
contraindication for Velcade (bortezomib) -
09.04.2008
Medicines Authority Circular P04/08 -
Over-the-counter cough and cold medicines for children
Medicines
Authority Circular No P03/2008 Re: New warnings and contraindications for
rosiglitazone - 25.01.2008
Medicines
Authority Circular No P02/2008 Re: Safety of Gardasil® (quadrivalent human
papillomavirus vaccine) - 25.01.2008
Medicines
Authority Circular No P01/2008 Re: Recommendation for the Withdrawal of the
Marketing Authorisation of Lumiracoxib-containing medicines- 10.01.2008
Medicines
Authority Circular No P19/2007 Re: Suspension of the Marketing Authorisation
of Aprotinin-containing medicines for systemic use - 22.11.2007
Medicines Authority Circular No P18/2007 Re: Benefit Risk Balance of
Prexige® (lumiracoxib) - 22.11.2007 (Attachment)
Medicines Authority Circular No P18/2007 Re: Benefit
Risk Balance of Prexige® (lumiracoxib) - 22.11.2007
Medicines
Authority Circular No P17/2007 Re: Suspension of marketing authorisations
for carisoprodol-containing medicinal products- 20.11.2007
Medicines
Authority Circular No P16/2007 Re: Protelos/Osseor® (Strontium ranelate) and
severe hypersensitivity reactions- 20.11.2007
Medicines
Authority Circular No P15/2007 Re: Benefit-Risk Profile of Avandia
(rosiglitazone) and Actos (pioglitazone) - 19.10.2007
Medicines
Authority Circular No P14/2007 Re: Benefit-Risk Profile of
Clobutinol-containing Medicinal Products- 19.10.2007
Medicines
Authority Circular No P13/2007 Re: Benefit-Risk Profile of
Nimesulide-containing Systemic Medicinal Products - 25.09.2007
Medicines
Authority Circular No P12/2007 Re: Lifting of Suspension of the Marketing
Authorisation for Viracept® (nelfinavir) - 25.09.2007
Medicines
Authority Circular No P11/2007 Re: Suspension of the Marketing Authorisation
for Viracept® (nelfinavir) - 07.08.2007
Medicines
Authority Circular No P10/2007 Re: Withdrawal of Veralipride-containing
Medicinal Products - 24.07 .2007
Medicines
Authority Circular No P09/2007 Re: Risk of Psychiatric Side-effects
associated with the Use of Acomplia (Rimonabant) - 20.07 .2007
Medicines
Authority Circular No P08/2007 Re: Benefit Risk Profile of Systemic
Piroxicam - 20.07.2007
Medicines
Authority Circular No P07/2007 Re: Suspension of the Marketing Authorisation
for Viracept® (nelfinavir) - 26.06.2007
Medicines
Authority Circular No P06/2007 Re: Cardiac Safety of Rosiglitazone (Avandia,
Avandamet, Avaglim).
Medicines
Authority Circular No P05/2007 Re: Safety of Dopamine Agonists - 05.04.2007
Medicines
Authority Circular No P04/2007 Re: Outcome on Benefit/Risk Review of Safety
of Ketek® (telithromycin). - 03.04.2007
Medicines Authority
Circular No P03/2007 Re:
European Medicines Agency statement on safety of Tamiflu – 23.03.2007
Medicines
Authority Circular No P02/2007 Re:
Pergolide and the risk of cardiac valvulopahty and fibrotic reactions.
- 15.02.2007
Medicines
Authority Circular No P01/2007 Re: Follow-up Information on the Safety of
Trasylol® (Aprotinin)
- 01.02.2007
Medicines Authority Circular No P11/2006 Re: Outcome
on Review of Cardiovascular Safety of Non-selective NSAIDs (Non-Steroidal
Anti-Inflammatory Drugs) - 25.10.2006
Medicines Authority Circular No P10/2006 Re: Licensed therapeutic
indications for Navidoxine 25mg tablets (Meclozine hydrochloride)
- 17.08.2006
Medicines
Authority Circular No P09/2006 Re: Serious Hepatic Reactions associated with
herbal medicinal products containing Cimicifugae Racemosae Rhizoma (Black
Cohosh) - 07.08.2006
Medicines Authority Circular No P08/2006 Update on
Prozac® (fluoxetine) and indication in children
- 09.06.2006
Medicines
Authority Circular No P07/2006 Re: Precautions on the use of Elidel®
(pimecrolimus) and Protopic®/Protopy® (tacrolimus) - 04.04.2006
Medicines
Authority Circular No P06/2006 Re: Update on Herceptin® (trastuzumab)
- 27.03.2006
Medicines
Authority Circular No P05/2006 RE: Albumin Therapy in Critically-ill
Patients - 20.03.2006
Medicines
Authority Circular No P04/2006 Isotretinoin-containing medicinal products
- 20.03.2006
Medicines
Authority Circular No P03/2006: Recent Study on Safety of Trasylol®
(Aprotinin) - 06/02/2006
Medicines
Authority Circular No P02/2006: Safety of Ketek (telithromycin)
- 30/01/2006
Medicines
Authority Circular No P01/2006:
Phenylpropanolamine (PPA) in medicinal
products - 25/01/2006
Medicines Authority Circular No
P21/2005: Tamiflu Safety Information - 15/12/2005
Medicines
Authority Circular No P20/2005: Safety of Tamiflu (oseltamivir) -
22/11/2005
Medicines
Authority Circular No P19/2005: Cardiovascular and gastointestinal safety
and serious skin reactions with non-selective NSAIDs (Non-Steroidal
Anti-Inflammatory Drugs) - 04/11/2005
Medicines
Authority Circular No P16/2005: Hexavac and concerns regarding decreased
long-term protection against hepatitis B - 20/09/2005
Medicines Authority Circular No
P15/2005: Non-Selective NSAIDs (Non-Steroidal Anti-Inflammatory Drugs) and
Cardiovascular Safety - 02/08/2005
Medicines
Authority Circular No P14/2005: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
and their recent association with an increased risk of myocardial infarction
(heart attack).
Statement in English.
Verżjoni
ta`stqarrija
bil-Malti.
Questions and Answers regarding
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and
their recent association with an increased risk of myocardial infarction
(heart attack).
Medicines Authority Circular No P12/2005:
Ongoing European and national
review of atypical antipsychotics and their association with an increased
risk of cerebrovascular adverse events (CVA) in elderly patients with
dementia - 17/05/2005
Medicines
Authority Circular No P11/2005:
Finalisation of Review of Serotonin-Selective Reuptake Inhibitors (SSRIs)
and Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
Medicines Authority Circular No P10/2005:
Suspension of Bextra® (valdecoxib)as
an Interim Measure
Medicines Authority
Circular No P09/2005: Quinine and the Risk of Thrombocytopenia
Medicines
Authority Circular No P02/2005: Compound Preparations containing Dextropropoxyphene and Paracetamol (Co-proxamol) and its indication for
mild to moderate pain
Updated Bextra SPC
Updated Dynastat SPC
Updated Onsenal SPC
Updated Celecoxib SPC
Updated Etoricoxib SPC
Medicines Authority Circular No P03/2005:
COX-2 Inhibitors Statement:-
English/Malti
Medicines
Authority Circular No P01/2005: Forthcoming Withdrawal of Thioridazine-containing Medicinal Products
Medicines Authority
Update No PLU04/2005: Products containing Glucosamine
Medicines Authority Update No PLU03/2005:
Ongoing review of COX-2
inhibitors, by the European Medicines Agency’s Committee for Medicinal
Products for Human Use (CHMP)
Medicines Authority
Update No PLU02/2005: VALDECOXIB
(Bextra®/Valdyn®) and PARECOXIB SODIUM (Dynastat®/Rayzon®) and
cardiovascular safety
Medicines Authority
Update No PLU01/2005: Celecoxib (Celebrex®) and cardiovascular
safety
Medicines Authority Update No PLU04/2004: Ritonovir
Medicines Authority Update No PLU03/2004: Implanon®: Europe adopts
the Dutch position - Implanon® still safe and effective
Medicines Authority Update No PLU02/2004: Extraordinary meeting of the European Medicines Agency
(EMEA)
scientific
committee, the Committee for Medicinal Products for Human use (CHMP)
held on 8
December 2004 on selective serotonin re-uptake inhibitors (SSRIs) and
serotonin and
norepinephrine re-uptake inhibitors (SNRIs) and their use in children
and adolescents.
Questions & Answers Regarding Cox-2 Inhibitors
Medicines Authority Update No
PLU01/2004:
Worldwide Withdrawal of Vioxx (Rofecoxib).
Press release in English.
Verżjoni
ta`stqarrija
bil-Malti
Vioxx - Questions and Answers
|
|
|
